Article
In this article, Robert A. Dowling, MD, describes some of the important differences and practical aspects of Stage 2 meaningful use as they related to "eligible professionals."
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
Experts share insights on next-generation NMIBC therapies
Study shows value of precision-based approaches in prostate cancer
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC